Ezetimibe Safety Profile and Oral Health Considerations

Mechanism of Action and General Safety Profile

The American College of Cardiology states that ezetimibe is a cholesterol absorption inhibitor that works by inhibiting the NPC1L1 protein in the small intestine, reducing cholesterol absorption from both dietary and biliary sources, and is FDA-approved as an adjunct to diet for reducing total cholesterol, LDL-C, apolipoprotein B, and non-HDL-C in patients with primary hyperlipidemia 1
Ezetimibe can be administered at 10 mg orally once daily, with or without food, as recommended by the American College of Cardiology 1

The American College of Cardiology reports that the most commonly reported adverse effects of ezetimibe monotherapy include upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and pain in extremities 1
When used in combination with statins, reported adverse effects include nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, and diarrhea, according to the American College of Cardiology 1

The American College of Cardiology recommends that ezetimibe is not used in patients with moderate to severe hepatic impairment 1
The American College of Cardiology also notes that persistent elevations in hepatic transaminases may occur with concomitant statin therapy 1
Cases of myopathy and rhabdomyolysis have been reported when ezetimibe was used alone or in combination with statin therapy, as stated by the American College of Cardiology 1

None of the major clinical guidelines, including those from the American College of Cardiology, mention gingivitis or any other oral health complications as known or potential side effects of ezetimibe 1, 2, 3, 4, 5
If a patient taking ezetimibe develops gingivitis, clinicians should consider other common causes such as poor oral hygiene, other medications the patient may be taking, or underlying systemic conditions that may predispose to gingival inflammation, according to the American College of Cardiology 1
Ezetimibe can be safely continued in patients with gingivitis, as there is no established causal relationship between the medication and this condition, as stated by the American College of Cardiology 1

The American College of Cardiology notes that ezetimibe combined with simvastatin showed no increased risk of hemorrhagic stroke or any bleeding-related adverse events compared to placebo in the SHARP trial of 9,270 patients with chronic kidney disease 6, 7
The American College of Cardiology guidelines state that ezetimibe "did not increase the risk for elevated hepatic transaminases, cancer, hemorrhagic stroke, or noncardiovascular mortality" 6, 7
The IMPROVE-IT trial demonstrated that ezetimibe plus simvastatin did not increase the risk of hemorrhagic stroke, cancer, or other serious bleeding complications 7

The American Heart Association and American College of Cardiology consistently report that ezetimibe's safety concerns are limited to potential hepatic transaminase elevations and rare myopathy/rhabdomyolysis when combined with statins, with no mention of bleeding risk as a concern 7, 8, 9, 10, 11

Large cardiovascular outcomes trials show that the overall incidence of adverse effects with ezetimibe is comparable to placebo, whether the drug is used as monotherapy or in combination with statins, indicating a favorable safety profile. 12

The 2022 BMJ guideline recommends that clinicians should not automatically attribute muscle pain, weakness, or other myopathic symptoms to ezetimibe (or to a nocebo effect) without a case‑by‑case investigation to determine the true cause. 12